Quarterly report [Sections 13 or 15(d)]

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.26.1
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Outstanding and nonvested as of December 31, 2025, Number of Shares [1] 4,566    
Granted, Number of Shares [2] 1,323    
Vested, Number of Shares (50)    
Forfeited, Number of Shares (51)    
Outstanding and nonvested as of March 31, 2026, Number of Shares [1] 5,788   4,566
Expected to vest as of March 31, 2026, Number of Shares [3] 5,106    
Outstanding and nonvested as of December 31, 2025, Weighted Average Grant Date Fair Value Per Share [1] $ 9.67    
Granted, Weighted Average Grant Date Fair Value Per Share [2] 19.26    
Vested, Weighted Average Grant Date Fair Value Per Share 17.58    
Forfeited, Weighted Average Grant Date Fair Value Per Share 10.26    
Outstanding and nonvested as of March 31, 2026, Weighted Average Grant Date Fair Value Per Share [1] 11.79   $ 9.67
Expected to vest as of March 31, 2026, Weighted Average Grant Date Fair Value Per Share [3] $ 11.64    
Stock Appreciation Rights (SARs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Awards Outstanding, Beginning Balance [4] 13,249    
Granted, Number of Awards 853    
Exercised, Number of Awards (86)    
Forfeited, Number of Awards [5] (28)    
Number of Awards Outstanding, Ending Balance [4] 13,988   13,249
Number of Awards Exercisable, Ending Balance [6] 6,332    
Number of Awards Vested and expected to vest, Ending Balance [6] 10,489    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [4] $ 11.07    
Granted, Weighted Average Exercise Price Per Award 19.26    
Exercised, Weighted Average Exercise Price Per Award 12.07    
Forfeited, Weighted Average Exercise Price Per Award [5] 28.68    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [4] 11.53   $ 11.07
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [6] 13.87    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [6] $ 12.66    
Weighted Average Remaining Contractual Term Outstanding [4] 7 years   7 years
Exercisable Weighted Average Remaining Contractual Term [6] 6 years 9 months 18 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest [6] 7 years 7 months 6 days    
Aggregate Intrinsic Value Outstanding [4],[7] $ 64.7   $ 45.4
Exercisable, Aggregate Intrinsic Value [6],[7] 21.4    
Aggregate Intrinsic Value, Vested and expected to vest [6],[7] $ 41.5    
Granted, Weighted Average Grant Date Fair Value Per Share $ 10.51 $ 4.52  
[1] Includes 2.8 million and 1.6 million performance-based restricted stock units as of March 31, 2026 and December 31, 2025, respectively, which represents the maximum amount that can vest.
[2] Includes 1.2 million performance-based restricted stock units.
[3] Includes 2.3 million performance-based restricted stock units.
[4] Includes 3.9 million and 3.9 million performance condition SARs as of March 31, 2026 and December 31, 2025, respectively.
[5] Includes less than 0.1 million performance condition SARs.
[6] Includes 0.5 million performance condition SARs.
[7] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.